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A B S T R A C T
Background
This is the second updated version of the Cochrane Review published in Issue 3, 2010 and first updated in Issue 5, 2013.
People with a primary brain tumour oGen experience depression, for which drug treatment may be prescribed. However, they are also at
high risk of epileptic seizures, cognitive impairment, and fatigue, all of which are potential adverse side effects of antidepressants. The
benefit, or harm, of pharmacological treatment of depression in people with a primary brain tumour is unclear.
Objectives
To assess the benefits and harms of pharmacological treatment of depression in people with a primary brain tumour.
Search methods
We updated the search to include CENTRAL, MEDLINE, Embase, and PsycINFO to September 2019. As in the original review, we also
handsearched Neuro-Oncology, Journal of Neuro-Oncology, Journal of Neurology, Neurosurgery and Psychiatry, and Journal of Clinical
Oncology: for the current update we handsearched the latest three years of articles from these journals (up to November 2019).
Selection criteria
We searched for all randomised controlled trials (RCTs), controlled clinical trials, cohort studies, and case-control studies of any
pharmacological treatment of depression in people with a histologically diagnosed primary brain tumour.
Data collection and analysis
No studies met the inclusion criteria.
Main results
We found no eligible studies evaluating the benefits of any pharmacological treatment of depression in people with a primary brain tumour.
Authors' conclusions
We identified no high-quality studies that investigated the value of pharmacological treatment of depression in people with a primary
brain tumour. RCTs and detailed prospective studies are required to inform the effective pharmacological treatment of this common and
important complication of brain tumours. Since the last version of this review none of the related new literature has provided additional
information to change these conclusions.
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P L A I N   L A N G U A G E   S U M M A R Y
Pharmacological treatment of depression in people with a primary brain tumour
The issue
People with brain tumours may experience epilepsy, memory problems, and fatigue. Depression is also common, and doctors might
choose to treat this with antidepressants, since antidepressants are thought to be effective in other patients. However, antidepressants
could be less effective, or could cause more side effects, in people with a primary brain tumour.
The aim of the review
We researched whether any drugs have been proven to be effective, and whether they cause significant side effects when prescribed to
treat depression in people with primary brain tumours.
Main findings
We searched the medical journal literature to find high-quality studies comparing the effectiveness of any one drug treatment for
depression in people with a brain tumour against another treatment. Despite a thorough search, we could not find any studies and so
cannot determine whether any drug is of benefit.
What are the conclusions?
We conclude that it is important to research whether drugs can treat depression safely and effectively in people with primary brain tumours.
Quality of evidence
No studies were eligible for this review.
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B A C K G R O U N D
This is the second updated version of the Cochrane Review
published in Issue 3, 2010 and first updated in Issue 5, 2013.
The reported prevalence of depression in cancer varies widely,
depending on the study population, diagnostic method, and
time at which people are assessed. In people with primary
brain tumours, the cross-sectional prevalence of depression as
determined by clinician-rated methods is approximately 20%
(Huang 2017). However, depression may pass undiagnosed
(Baltenberger 2014), and, even when identified, may be
inadequately treated (Litofsky 2009; Sharpe 2004).
Description of the condition
Primary brain tumours
The global incidence of primary brain tumours is estimated to be
10.8 per 100,000 person-years (de Robles 2015), and increasing
(Patel 2019). As a group, primary brain tumours differ from
metastatic tumours, which spread to the brain from cancer
elsewhere in the body. Primary brain tumours can be categorised
according to World Health Organization (WHO) criteria reflecting
their cell of origin, degree of malignancy, and molecular parameters
(Louis 2016). The most common type of malignant primary brain
tumour is glioma (Lapointe 2018), and most gliomas (70% to
80%) are 'high-grade' aggressive tumours. With current treatment,
approximately 10% of people with the most aggressive form of
glioma (glioblastoma multiforme, GBM) may survive five years
aGer diagnosis (Stupp 2009). A minority of gliomas are slowly
growing 'low-grade' tumours associated with a median survival
of approximately seven years (Claus 2015). Low-grade gliomas are
more frequently associated with epileptic seizures than high-grade
tumours (Pallud 2019). Meningiomas are another common type of
primary brain tumour, which occurs more frequently in women and
the elderly and may be cured by surgery (Wiemels 2010).
Depression
Major depressive disorder (depression) is a clinical syndrome
of sadness or loss of interest or/enjoyment, or both; negative
beliefs (e.g. feelings of guilt, hopelessness, or low self-esteem);
psychomotor abnormalities (e.g. fatigue and psychomotor
retardation); and biological manifestations (e.g. sleep and appetite
disturbances) (Gelder 2012). Because sadness, negative thoughts
(e.g. about loss of health or death) and physical symptoms can
be normal in people with cancer, the gold-standard method of
diagnosing depression is a structured clinical interview conducted
by a specialist in mental health (APA 2016). Significant depressive
symptoms can also be identified in people with cancer using rating
scales (e.g. Zigmond 1983), which use cut-off scores to estimate the
likelihood of depression and, being easier to administer, are oGen
used as a 'proxy' diagnosis in clinical research.
Description of the intervention
Antidepressants are recommended as a first-line treatment for
moderate to severe depression in national guidelines (APA
2016; NICE 2009). Three prominent pharmacological classes
of antidepressant are: selective serotonin re-uptake inhibitors
(SSRI), tricyclic antidepressants (TCA), and monoamine oxidase
inhibitors (MAOI). A fourth class of newer, 'second-generation'
compounds is chemically diverse. Other drug classes, for
example psychostimulants, Weitzner 1999, or acetylcholinesterase
inhibitors, Shaw 2006, have also been proposed for use in
people with primary brain tumours. Although the precise mode of
action is unknown (Moncrieff 2004), meta-analyses of randomised
controlled trials (RCTs) enrolling people without brain tumours
report antidepressants to be effective in the depressed elderly,
Mottram 2006, and in those with chronic low-level depression, Lima
2005, or severe or psychotic depression, Wijkstra 2005.
How the intervention might work
Antidepressants may reduce depressive symptoms in people with
other neurological illnesses (Hackett 2008). In the physically ill,
however, a limited response to treatment and high relapse rates
may oGen be observed (Iosifescu 2004). Non-pharmacological
treatments for depression (e.g. psychotherapy) are not covered in
this review.
Why it is important to do this review
Clinical depression can affect up to 20% of people with a primary
brain tumour in the first eight months aGer diagnosis (Rooney
2011), and can have important consequences for the affected
person and their family. In glioma, depression has been associated
with physical functional impairment (Rooney 2011), cognitive
impairment (Sayyah 2016), reduced quality of life (Mainio 2006a),
higher mortality (Gathinji 2009; Litofsky 2004; Mainio 2006b), a
greater frequency of medical complications (Litofsky 2004), and
reduced work productivity (Feuerstein 2007). People with glioma
may have the highest risk of all people with cancer of psychiatric
hospitalisation in the year following diagnosis (Dalton 2009).
Depression is a strong risk factor for suicide, Rihmer 2007, and
epilepsy, Hesdorffer 2000, in people without a brain tumour. If
depression in people with a primary brain tumour was effectively
treated, personal or family suffering could potentially be reduced.
However, it is possible that the side effects of antidepressants
outweigh any benefit. Antidepressants might lower seizure
threshold (Hill 2015), impair memory (Sayyah 2016), or cause
fatigue (Cassano 2004). People with primary brain tumours are
already at high risk of these complications. Despite clinical
uncertainty, the effectiveness and potential adverse impact of
pharmacotherapy for depression in primary brain tumours has not
been systematically reviewed.
O B J E C T I V E S
To assess the benefits and harms of pharmacological treatment of
depression in people with a primary brain tumour.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For evidence of efficacy we aimed to include:
• RCTs.
For evidence of adverse effects we also aimed to include:
• controlled clinical trials;
• cohort studies;
• case-control studies.
Pharmacological treatment of depression in people with a primary brain tumour (Review)
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• Adults (aged 18 years and over)
• A diagnosis of depression at baseline (diagnosed by any
validated method and satisfying the original trial authors that
pharmacological treatment of depression was reasonable and
necessary)
• A comorbid histological diagnosis of any primary brain tumour
Exclusion criteria
• Studies recruiting only people with metastatic (i.e. non-primary)
brain tumours were excluded.
Types of interventions
Any drug prescribed to treat depression compared, where relevant,
with a control group receiving any other treatment. We anticipated
that the most common drug class would be an antidepressant,
but any category of prescription drug was eligible. Studies
administering only unlicensed herbal remedies (e.g. St John's wort)
were excluded.
Types of outcome measures
Primary outcomes
The primary outcome was change in depression at final follow-
up. We anticipated that this could be measured in several different
ways:
• the mean change in depression scale score (measured by
a validated scale, e.g. Center for Epidemiological Studies-
Depression Scale (CES-D; Radloff 1977); Hospital Anxiety and
Depression Scale (HADS; Zigmond 1983); Beck Depression
Inventory-II (BDI-II; Beck 1996);
• the proportion of participants meeting predefined criteria for
improvement in scale score;
• changes in the proportion of participants with a categorical
diagnosis of depression ('present' or 'absent').
Where both categorical (present or absent) and continuous (scale
score) depression data were presented, we aimed to analyse both.
Secondary outcomes
• Health-related quality of life (measured by a validated scale, e.g.
using the European Organisation for Research and Treatment of
Cancer QLQ-C30 (EORTC QLQ-C30; Aaronson 1993); Functional
Assessment of Cancer Therapy (FACT; Weitzner 1995); 36-item
Short Form Health Survey (SF-36; McHorney 1993).
• General emotional distress (measured by a validated scale, e.g.
Hospital Anxiety and Depression Scale (HADS; Zigmond 1983).
• Length of time from diagnosis of a primary brain tumour to
death.
Although antidepressants can have many side effects, we identified
those we considered most likely to occur in people with a brain
tumour:
• seizure frequency (measured by participant or carer report);
• cognitive dysfunction (e.g. poor memory, measured by validated
neuropsychological testing);
• fatigue (measured by a validated rating scale, e.g. Brief Fatigue
Inventory (Mendoza 1999), Functional Assessment of Cancer
Therapy - Fatigue (Yellen 1997), Multidimensional Fatigue
Symptom Inventory (Stein 2004)).
Search methods for identification of studies
We ran searches for the original review in July 2009. We ran the
subsequent (update) search in October 2012, and the latest search
in September 2019.
Electronic searches
For this review update, we searched the following databases up to
30 September 2019:
• the Cochrane Central Register of Controlled Trials (CENTRAL;
2019, Issue 9) in the Cochrane Library;
• MEDLINE via Ovid (October 2012, week 3 to September 2019,
week 3);
• Embase via Ovid (2012, week 42 to 2019, week 39);
• PsycINFO (October 2012 to September 2019).
We had previously searched the British Nursing Index, LILACS (Latin
American and Caribbean Health Science Information database),
PSYNDEX, the NHS National Research Register, the NHS Centre for
Reviews and Dissemination's Database of Abstracts of Reviews of
Effects (DARE), and Web of Knowledge (covering Science SciSearch,
Social Sciences Citation Index, and Biological Abstracts) (to July
2009).
In the original review we constructed individual search strategies
for each database (see Appendix 1 to Appendix 2). In the update,
we amended search strategies where relevant to remove duplicate
terms (Appendix 3 to Appendix 4). Because we aimed to include
studies other than RCTs, we conducted topic searches only.
Searching other resources
For the original review we contacted:
• pharmaceutical companies manufacturing all antidepressants
listed in the British National Formulary (BNF);
• International Network of Agencies for HTA (INAHTA);
• British Library Document Supply Centre (BLDSC).
This yielded no relevant information and was not repeated for the
update.
We handsearched the following journals (up to November 2019) for
articles and conference abstracts:
• Journal of Neurology, Neurosurgery and Psychiatry;
• Journal of Neuro-Oncology;
• Journal of Clinical Oncology;
• Neuro-Oncology.
We aimed to handsearch:
• reference lists of eligible studies;
• book chapters identified in the reference lists of eligible studies.
Pharmacological treatment of depression in people with a primary brain tumour (Review)
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Data collection and analysis
Selection of studies
Two review authors (ZB and SH) initially filtered studies based
on the title and abstract. We then obtained full copies of
potentially relevant studies, which two review authors (ZB and
SH) independently assessed for eligibility, supervised by an
experienced research fellow (FB).
Data extraction and management
Two review authors (ZB and SH) were to independently extract data
from eligible studies using a predefined data extraction form. For
the categorical outcome of depression, we planned to extract the
number of depressed participants in each arm at final follow-up
in order to estimate risk ratio (RR). For continuous outcomes, we
planned to extract the mean and standard deviation (SD) of the
outcome of interest in each arm at final follow-up. We planned to
estimate from the means and SDs whether the data were skewed;
if they were, we would write to the study authors requesting the
mean and SDs of log transformed data. For time-to-death data, we
planned to extract the hazard ratio (HR) and its variance from trial
reports; if these were not presented, we would attempt to either
estimate them or extract relevant data from Kaplan-Meier survival
curves. Failing this, we would estimate RR as outlined above. One
review author (ZB or SH) would enter data into Review Manager 5,
and the other review author would check the data entry (Review
Manager 2014).
Assessment of risk of bias in included studies
We intended to assess and report on the methodological risk of
bias of included studies in accordance with the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011), which
recommends the explicit reporting of RCTs, using the 'Risk of bias'
1 tool, including all of the domains in this tool: random sequence
generation; allocation concealment; blinding of participants and
personnel; blinding of outcome assessment; incomplete outcome
data; selective reporting; and other sources of bias. We would
categorise risk of bias as high, low, or unclear, and present this
information in a ‘Risk of bias’ table. We would discuss the risk of
bias in the included studies, resolving any persisting disagreements
between the authors by consulting a third review author.
Measures of treatment effect
When summarising the categorical outcome of depression, we
planned to calculate risk ratios (RR) with 95% confidence intervals
(CI). When comparing continuous outcome data from studies
using different rating scales, we would use the standardised mean
difference (SMD); we would calculate the mean difference (MD) for
studies using the same scale. Both would be presented with 95%
CI for individual outcomes in individual studies. For time-to-death
data, we planned to pool HRs using the generic inverse variance
facility of Review Manager 5 (Review Manager 2014). We planned
to analyse secondary outcomes as continuous variables only (MDs
or SMDs). Where possible, participants were to be analysed in the
groups to which they had been randomised, irrespective of the
treatment they actually received.
Unit of analysis issues
We would take different levels of randomisation (e.g. at the level
of participants or groups) into account. When there were long-term
follow-up assessments available within trials, we would analyse
outcomes for two different follow-up categories: short term (i.e. 0
to 6 months); or medium to long term (i.e. 6 months and more).
If we identified studies with multiple intervention groups, we
would make pair-wise comparisons between all possible pairs of
intervention groups. We would ensure that double-counting of
participants in the analysis did not occur.
Dealing with missing data
We would calculate missing measures of uncertainty (e.g. CIs and
SDs) where possible or contact the study authors to request the
data. We did not intend to impute missing data.
We aimed to record the number of participants in each intervention
arm whose outcomes were not reported at the end of the study,
noting if loss to follow-up was not reported. Controlled non-
randomised studies were to be similarly assessed, with analysis of
whether:
• the treatment and comparison groups were comparable at
baseline;
• the analysis was adjusted for potential confounding factors.
If as a result of this assessment we considered it likely that the study
was biased, we would not include it in meta-analysis.
Assessment of heterogeneity
We aimed to calculate statistical heterogeneity using the I2 statistic,
considering an I2 value of > 50% as evidence of substantial
heterogeneity, and visually inspect forest plots for heterogeneity. As
we expected a certain degree of heterogeneity, we planned to use a
random-effects model for meta-analysis.
Assessment of reporting biases
If at least 10 studies were included, we would draw funnel plots
of treatment effect versus precision with the data from all studies
(Higgins 2011). We would visually inspect the funnel plots to assess
whether there had been selective reporting of outcomes.
Data synthesis
If outcomes differed amongst included studies, we would pool
them if measuring the same construct, or report on each outcome
systematically for those not measuring the same construct.
We would perform a meta-analysis if we included two or more RCTs
with a low risk of bias in which the study population, intervention,
and outcome measures were comparable. We would present this
in a ‘Summary of findings’ table, and would include the primary
and secondary outcomes listed above. For each outcome, we
would report the number of participants, the overall quality of the
evidence according to the GRADE approach, and the effect size. If a
meta-analysis was not possible, we would synthesise the findings
of the included studies in a table, employing the GRADE levels of
evidence (Higgins 2011). We would report the individual effect sizes
of the studies and 95% CI. We would use Review Manager 5 for
analyses (Review Manager 2014).
Subgroup analysis and investigation of heterogeneity
If we included a sufficient number of studies, that is at least
two for each subgroup, we would perform subgroup analysis by
antidepressant class, tumour histology, and WHO grade of tumour.
Pharmacological treatment of depression in people with a primary brain tumour (Review)
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Sensitivity analysis
We aimed to conduct sensitivity analyses by excluding studies
that did not report adequate: (i) concealment of allocation or (ii)
blinding of the outcome assessor.
R E S U L T S
Description of studies
Results of the search
A PRISMA diagram displaying records identified and screened is
shown in Figure 1.
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Figure 1.   PRISMA study flow diagram.
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Included studies
We found no eligible studies for any of our primary or secondary
outcomes.
Excluded studies
Studies that were of interest to the research question but did not
meet the inclusion criteria of the review are as follows.
Knudsen-Baas 2018 conducted a cohort study reporting the
prevalence and associations of psychotropic medication, including
antidepressants, in a Danish population-based study. The authors
did not test the efficacy of any antidepressant interventions, or
measure specific side effects.
Boele 2013 tested a psychostimulant (modafinil) in 37 participants
with primary brain tumours. In this RCT, the researchers screened
for fatigue, which was the primary outcome. Depression was
included as a secondary outcome, but participation was not limited
to depressed people.
Blackhall 2009 conducted a similar study looking at modafinil to
treat cancer-related fatigue in multiple cancers, and also looked
at depression along with neurocognitive function as a secondary
outcome. The authors reported some improvement in anxiety
and depression, but participation in the study was not limited to
depressed people.
Wirz 2010 also conducted an intervention study testing modafinil
for reducing fatigue in people with cancer who were undergoing
both treatment and pain relief, but did not select people with
depression. No people with primary brain tumours were included.
Gehring 2012 compared two psychostimulants (methylphenidate
and modafinil) in 24 people with primary brain tumours in an RCT.
Depressive symptoms were assessed as a secondary outcome only,
and participation was not limited to depressed people.
Maschio 2013 conducted an RCT to determine the effect of
pregabalin on seizure control in people with brain tumour.
However, depression was a secondary outcome only, and
participants did not have to suffer from depression to be included.
Walker 2010 looked at the benefit of using tricyclic antidepressants
for mortality reduction in people with glioma or colorectal cancer.
They did not investigate management of depression, but found that
tricyclic antidepressants did not improve mortality.
Attia 2012 conducted a phase II trial to investigate whether the
botanical product Ginkgo biloba had any effect on improving
cognitive functioning in irradiated people with brain tumours.
Mood (depression) was included as a secondary outcome only, and
participants were not selected based on an existing diagnosis of
depression.
Gothelf 2005 conducted a pilot study to assess safety and
tolerability of a selective serotonin re-uptake inhibitor (SSRI)
antidepressant (fluvoxamine) in children with cancer and comorbid
depression or anxiety disorders (Gothelf 2005). The treatment
was well tolerated and appeared to reduce depressive symptoms.
Participants did not include adults, and only one participant was
diagnosed with a brain tumour.
Wellisch 2006 conducted an RCT of a psychostimulant
(methylphenidate) in people with brain tumour, with depression as
a secondary outcome. However, it was not clear from the published
conference abstract whether participation was limited to people
with depression, and we were unable to contact the authors for
clarification.
Morrow 2003 reported an RCT of an antidepressant (paroxetine) in a
mixed population of people with cancer, including those with brain
tumours. Although depression was measured as an outcome, the
intervention was given primarily to treat fatigue, and participation
was not limited to people with depression. Data for the small
number of participants with brain tumours were not reported
separately.
Moss 2006 conducted an open-label phase II trial of an
antidepressant (bupropion) on fatigue in a mixed population
of people with cancer, including those with brain tumour,
and measured levels of depression. However, participation was
restricted to people with high levels of fatigue, not depression.
Shaw 2006 enrolled 35 participants with brain tumours to an
open-label phase II trial of an acetylcholinesterase inhibitor
(donepezil) and measured depression using a rating scale.
However, participation was not limited to people with depression.
Meyers 1998 evaluated the effects of a psychostimulant
(methylphenidate) in an open-label phase II trial of 30 participants
with high-grade glioma, measuring depressive symptom severity
amongst other outcomes. However, the authors explicitly excluded
individuals with major depression at study baseline.
Litofsky 2004 conducted a prospective cohort study of adults with
high-grade glioma, examining the relationship between depression
and survival in glioma. However, the authors did not systematically
prescribe treatment for depression and did not limit participation
to people with depression.
Koval'chuk 2007 conducted a prospective cohort study of 225
participants following operation for brain tumour. The authors
measured depression amongst other outcomes, and assessed
the influence of different antidepressants on the postoperative
normalisation of mood. However, again, participation was not
limited to people with depression.
Caudill 2011 conducted a retrospective cohort study of the
frequency and toxicity of SSRI prescription in 160 people with
glioblastoma presenting to a tertiary neuro-oncology service over
a 10-year period. The authors reported that being prescribed SSRIs
was associated with improved survival at two years postdiagnosis,
aGer controlling for relevant confounders. Participants being
prescribed an SSRI reported similar levels of toxicities as those on
no SSRI. However, antidepressant prescription was uncontrolled,
and the study was not limited to people with depression.
Other studies that were ineligible on methodological grounds were
a small uncontrolled case series, Rabey 1985, and a single case
study, Oyewumi 1981.
Ongoing studies
We identified one ongoing study. The PASSION trial is testing the
effect of ketamine on perioperative depressive symptoms in people
undergoing brain tumour resection. Only adults with moderate
Pharmacological treatment of depression in people with a primary brain tumour (Review)
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to severe depressive symptoms will be recruited. The trial was
scheduled to finish in February 2019, but to date no results have
been published (Zhou 2018). We contacted the authors but have not
received a response.
Risk of bias in included studies
No eligible studies have been identified.
Effects of interventions
No eligible studies have been identified.
D I S C U S S I O N
Summary of main results
We found no eligible studies of the pharmacological treatment of
depression in adults with primary brain tumours. Several studies
have examined related aspects of drug treatment of symptoms
in people with a primary brain tumour. However, all trials to
date recruited both depressed and non-depressed participants,
and all cohort studies reported usual clinical care rather than
systematically evaluating a specific treatment. Consequently, the
results do not easily generalise to the question that is the focus of
this review, that is treating depressed people with primary brain
tumours. The lack of evidence is an important finding because
depression is a common complication of brain tumours (Huang
2017; Litofsky 2004), with serious consequences for quality of life,
Gazzotti 2011, and possibly survival (Gathinji 2009; Litofsky 2004;
Mainio 2006b).
Although national guidelines for the treatment of depression exist
(NICE 2009), they cannot have been based on evidence specific
to brain tumours because we have been unable to identify any
studies that were eligible for this review. Antidepressants appear
to be effective in people with other medical illnesses, but the
effectiveness in people with a primary brain tumour should not
be assumed. Brain tumours are rapidly progressive, biologically
active, and with significant structural and functional effects upon
the main organ implicated in depression. Brain tumours (and
their surgical treatment) may disrupt neuronal circuits crucial to
the experience of emotion (Litofsky 2009), or alter local levels of
biochemical mediators (Mainio 2005). Antiepileptic drugs can affect
the bioavailability of antidepressants (Hachad 2002; Spina 2016),
and corticosteroids have been associated with mood changes in
glioma (Litofsky 2004). There are reasons to be cautious about
assuming that antidepressants are effective in people with primary
brain tumours.
Brain tumours are also associated with epilepsy, cognitive
dysfunction, and fatigue (Ruda 2010; Wen 2008), which are
recognised side effects of antidepressants (Cassano 2004;
Montgomery 2005; Peretti 2000). It is important to highlight the lack
of evidence about the possible adverse effects of antidepressants
in this high-risk group. Antidepressants could also impact on
these outcomes, since depression has itself been associated with
epilepsy (Mula 2017), impaired cognition (Rock 2014), and fatigue
(Moss 2006).
Overall completeness and applicability of evidence
Nine excluded studies used a pharmacological agent other than an
antidepressant (a psychostimulant, acetylcholinesterase inhibitor,
antiepileptic drug, or botanical product). These drugs could help
treat a wider range of symptoms than antidepressants. However, to
date no studies have primarily evaluated the benefit, or harm, of
pharmacological treatment of depression in people with a primary
brain tumour. Direct study of this question requires that eligibility
is restricted to people with high levels of depression at baseline.
Quality of the evidence
With no eligible studies identified, we could not assess the quality
of evidence according to the GRADE levels of evidence.
Potential biases in the review process
We searched three databases electronically and handsearched four
journals for this update (we previously searched more databases in
the original review). We searched for ongoing trials, and contacted
the authors for any unpublished data (Zhou 2018). Despite this
rigorous review process, the possibility remains that we did not
identify an eligible trial. Regular reviews of this update are therefore
needed.
Agreements and disagreements with other studies or
reviews
Over 20 years ago, Weitzner and colleagues argued that people with
primary brain tumours should receive psychotropic medication for
depression if indicated (Weitzner 1999). However, now as then, no
RCTs have studied the effectiveness of drug treatment for clinical
depression in people with primary brain tumours. Several research
groups recognise the potentially profound impact of depression
on quality of life in people with primary brain tumours (Huang
2017; Litofsky 2009; Pangilinan 2007); yet people living with a
primary brain tumour may in theory be more sensitive to adverse
side effects from the drugs used to treat depression. The risk
of antidepressant-associated delirium, seizures, and drug-drug
interactions remains unknown (Price 2008). As a result, the risk-
benefit of treating depression with drugs in these patients remains
unclear. Consequently, there is general agreement in the need
for RCTs of pharmacological treatment of clinical depression in
people with a primary brain tumour ((Huang 2017; Litofsky 2009;
Pangilinan 2007; Price 2008; Weitzner 1999).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Since the last version of this review, no new relevant studies
have provided additional information to change our conclusions.
There is currently no high-quality evidence as to whether
pharmacological treatments for depression in people with primary
brain tumours are either effective or harmful. Best practice
would suggest that doctors treating depressed people with a
primary brain tumour discuss the lack of evidence with the
individual, document the views of the patient, and use their clinical
judgement. If drug treatment is started, close follow-up may help
detect any adverse effects.
Implications for research
Detailed prospective studies and randomised controlled trials
addressing the risks and benefits of antidepressants are vital.
Important research questions include whether, amongst people
with a primary brain tumour and depression, there is any evidence
that treatment:
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• is effective in treating depression;
• has clinically significant effects on seizure frequency, fatigue,
and cognition;
• has clinically significant pharmacokinetic interactions with
antiepileptic drugs or chemotherapy;
• has a clinically significant effect on survival.
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Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Attia 2012 Depression was not the primary outcome; the study did not require participants to have depres-
sion. The drug used, Gingko biloba, is a herbal supplement unlicenced for the treatment of depres-
sion.
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Study Reason for exclusion
Blackhall 2009 Depression was not the primary outcome, and participants were not explicitly screened for depres-
sion.
Boele 2013 Depression was not the primary outcome, and participants were not explicitly screened for depres-
sion.
Caudill 2011 Treatment of depression was based on routine clinical care (not systematically controlled).
Gehring 2012 Depression was not the primary outcome, and participants were not explicitly screened for depres-
sion.
Gothelf 2005 No adult brain tumour patients included.
Knudsen-Baas 2018 Not an intervention study
Koval'chuk 2007 Depression was not an inclusion criterion.
Litofsky 2004 Treatment of depression was not systematically controlled. Depression was not an inclusion crite-
rion.
Maschio 2013 Depression was not the primary outcome, and participants were not explicitly screened for depres-
sion.
Meyers 1998 Patients with severe depression were excluded, and the study was not limited to those with milder
depression.
Morrow 2003 Depression was not an inclusion criterion. Data for brain tumour patients were not presented sepa-
rately.
Moss 2006 Depression was not an inclusion criterion. Data for brain tumour patients were not presented sepa-
rately.
Oyewumi 1981 Single case study
Rabey 1985 3 case studies; brain tumour not diagnosed at time of antidepressant prescription
Shaw 2006 Depression was not an inclusion criterion.
Walker 2010 Did not investigate antidepressant as treatment for depression
Wellisch 2006 Could not confirm whether depression was an inclusion criterion
Wirz 2010 No patients with primary brain tumours included.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Effect of low-dose ketamine on PerioperAtive depreSsive Symptoms in patients undergoing In-
tracranial tumOr resectioN (PASSION): study protocol for a randomized controlled trial
Methods Single-centre randomised, placebo controlled, and double-blinded; 1:1 split between treatment
and placebo arms. Participants randomised and stratified by severity of perioperative depression
symptoms (moderate and severe).
Zhou 2018 
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Participants 80
Interventions Participants in the ketamine arm receive a low-dose ketamine infusion, and participants in the
placebo arm receive a saline infusion.
Outcomes Primary endpoint is perioperative depressive symptoms 3 days postsurgery.
Starting date 2017
Contact information Ruguan Han, Department of Anesthesiology, Beijing Tiantan Hospital, Capital Medical University,





A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Conducted 22 July 2009
Ovid MEDLINE (R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE (R) 1950 to present (July week 2 2009)
1. exp depressive disorder/~






8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp Glioma/






16. 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Antidepressive Agents/
18. exp Serotonin Uptake Inhibitors/
19. exp Monoamine Oxidase Inhibitors/






26. Antidepressive Agents, Tricyclic/
27. Antidepressive Agents, Second Generation/
28. 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27
29. 8 and 16 and 28
30. (animals not (humans and animals)).sh.
31. 29 not 30
(n = 57)
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Appendix 2. Web of Knowledge search strategy
Searched 22 July 2009
www.isiknowledge.com
Topic=(depression OR depressive disorder OR major depression OR mood disorder OR depress* OR affectiv* OR dysthym* OR mood*)
AND Topic=(antidepress* OR SSRI OR MAOI OR TCA) AND Topic=(brain neoplas* OR brain tumo* OR glioma OR astrocytoma OR
oligodendroglioma OR meningioma)
(n = 306)
Appendix 3. MEDLINE updated search strategy
1 exp Depressive Disorder/
2 Depression/
3 exp Mood Disorders/
4 depress*.mp.
5 ((affective or mood) adj disorder*).mp.
6 1 or 2 or 3 or 4 or 5
7 exp Brain Neoplasms/
8 exp Glioma/
9 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.
10 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.
11 7 or 8 or 9 or 10
12 drug therapy.fs.
13 exp Antidepressive Agents/
14 exp Serotonin Uptake Inhibitors/
15 exp Monoamine Oxidase Inhibitors/
16 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.
17 12 or 13 or 14 or 15 or 16
18 6 and 11 and 17
Appendix 4. CENTRAL updated search strategy
#1 MeSH descriptor: [Depressive Disorder] explode all trees
#2 MeSH descriptor: [Depression] explode all trees
#3 MeSH descriptor: [Mood Disorders] explode all trees
#4 depress*
#5 (affective or mood) near disorder*
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Brain Neoplasms] explode all trees
#8 MeSH descriptor: [Glioma] explode all trees
#9 brain near/5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)
#10 glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*
#11 #7 or #8 or #9 or #10
#12 Any MeSH descriptor with qualifier(s): [Drug therapy - DT] in all MeSH products
#13 MeSH descriptor: [Antidepressive Agents] explode all trees
#14 MeSH descriptor: [Serotonin Uptake Inhibitors] explode all trees
#15 MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees
#16 SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*
#17 #12 or #13 or #14 or #15 or #16
#18 #6 and #11 and #17
Appendix 5. CENTRAL search strategy
Searched 22 July 2009
EBM Reviews - Cochrane Central Register of Controlled Trials 3rd Quarter 2009
1. Glioma/
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10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
11. exp Antidepressive Agents/
12. exp Antidepressive Agents, Second-Generation/
13. Antidepressive Agents, Tricyclic/
14. Serotonin Uptake Inhibitors/






21. exp Drug Therapy/
22. pharmacotherapy.mp.
23. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22







31. 24 or 25 or 26 or 27 or 28 or 29 or 30
32. 10 and 23 and 31
(n = 8)
Appendix 6. LILACS search strategy
Searched 22 July 2009
1. Depression OR Depressive OR Mood OR Affect
2. Glioma OR Glioblastoma OR Meningioma OR Brain neoplasm
3. Antidepressant OR Antidepressive OR SSRI OR MAOI OR TCA
4. 1 and 2 and 3
(n = 0)
Appendix 7. PSYNDEX search strategy
Searched 22 July 2009
(all search terms free text)
1. Depression OR Depressive OR Mood OR Affectiv?
2. Gliom? OR gehirntumo? OR Krebs OR Astrocytom? Or Oligodendrogliom? OR Meningiom?
3. Antidepress OR Serotonin OR SSRI OR MAOI OR TCA OR Pharmacotherap?
4. 1 and 2 and 3
(n = 1)
Appendix 8. National Research Register archive search strategy
Searched 22 July 2009
(Database was only active until 2007)
1. "Glioma"
(n = 272)
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Appendix 9. DARE search strategy
Searched 22 July 2009
















16. 11 or 12 or 13 or 14 or 15
17. 4 and 10 and 16
(n = 0)
Appendix 10. Embase search strategy
Conducted 22 July 2009
EMBASE 1980 to 2009 Week 29
1. exp Depression/




6. 1 or 2 or 3 or 4 or 5
7. exp Glioma/
8. exp Brain Tumor/
9. Astrocytoma/
10.Meningioma/
11. (glioma* or brain tumo* or astrocytoma* or meningioma*).ti,ab.
12. 7 or 8 or 9 or 10 or 11
13. exp Antidepressant Agent/
14. Monoamine Oxidase Inhibitor/
15. Tricyclic Antidepressant Agent/
16. Serotonin Uptake Inhibitor/
17. (antidepress* or SSRI* or MAOI* or TCA* or tricyclic*).ti,ab.
18. 13 or 14 or 15 or 16 or 17
19. animal.sh
20. human.sh
21. 19 not (19 and 20)
22. 6 and 12 and 18
23. 22 not 21
(n = 287)
Appendix 11. PsycINFO search strategy
Searched 22 July 2009
PsycINFO 1806 to July Week 2 2009
1. exp Endogenous Depression/
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2. exp Reactive Depression/
3. exp Major Depression/
4. exp Mental Disorders/
5. exp Affective Disorders/
6. (depress$ or mood$ or affective$ or dysthym$).ab,ti.
7. 1 or 2 or 3 or 4 or 5 or 6





13. (glioma$ or brain tumo$ or astrocytoma$ or meningioma$ or oligodendroglioma$).ab,ti.
14. 8 or 9 or 10 or 11 or 12 or 13
15. exp Drug Therapy/
16. pharmacotherapy.mp.
17. exp Antidepressant Drugs/
18. exp Tricyclic Antidepressant Drugs/
19. exp Monoamine Oxidase Inhibitors/
20. exp Serotonin Reuptake Inhibitors/
21. (antidepress$ or SSRI$ or MAOI$ or TCA$ or tricyclic$ or drug therap$ or pharmacotherap$).ab,ti.
22.15 or 16 or 17 or 18 or 19 or 20 or 21
23. 7 and 14 and 22
(n = 39)
Appendix 12. Embase updated search strategy
1 exp mood disorder/
2 depress*.mp.
3 ((affective or mood) adj disorder).mp.
4 1 or 2 or 3
5 exp brain tumor/
6 exp glioma/
7 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.
8 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.
9 5 or 6 or 7 or 8
10 dt.fs.
11 exp antidepressant agent/
12 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.
13 10 or 11 or 12
14 4 and 9 and 13
Appendix 13. PsycINFO updated search strategy
1 exp affective disorders/
2 depress*.mp.
3 ((affective or mood) adj disorder*).mp.
4 1 or 2 or 3
5 brain neoplasms/
6 glioma/
7 (brain adj5 (tumor* or tumour* or neoplas* or malignan* or cancer* or carcinoma*)).mp.
8 (glioma* or astrocytoma* or meningioma* or oligodendroglioma* or glioblastoma*).mp.
9 5 or 6 or 7 or 8
10 exp drug therapy/
11 exp antidepressant drugs/
12 exp Serotonin Reuptake Inhibitors/
13 exp Monoamine Oxidase Inhibitors/
14 (SSRI* or TCA* or MAOI* or tricyclic* or antidepress* or anti-depress*).mp.
15 10 or 11 or 12 or 13 or 14
16 4 and 9 and 15
Appendix 14. British Nursing Index search strategy
Searched 22 July 2009
Pharmacological treatment of depression in people with a primary brain tumour (Review)
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British Nursing Index and Archive 1985 to July 2009
1. exp depression/
2. exp psychiatric disorders/
3. (depress$ or mood$ or affectiv$ or dysthym$).ti,ab.
4. 1 or 2 or 3
5. exp cancer/
6. (glioma$ or brain tumo$ or astrocytoma$ or meningioma$ or oligodendroglioma$).ti,ab.
7. 5 or 6
8. exp Drug Therapy/




13. (antidepress$ or SSRI$ or MAOI$ or TCA$ or drug therap$ or pharmacotherap$).ti,ab.
14. 8 or 9 or 10 or 11 or 12 or 13
15. 4 and 7 and 14
(n = 20)
W H A T ' S   N E W
 
Date Event Description
15 July 2020 New citation required but conclusions
have not changed
Nine new studies added to excluded studies (Attia 2012; Black-
hall 2009; Boele 2013; Gehring 2012; Gothelf 2005; Knudsen-Baas
2018; Maschio 2013; Walker 2010; Wirz 2010). One new study was
added to ongoing studies (Zhou 2018). The update has not al-
tered the conclusions from the last publication of this review.
15 July 2020 New search has been performed Search updated up to September 2019 and review updated ac-
cordingly.
 
H I S T O R Y
Protocol first published: Issue 1, 2008
Review first published: Issue 3, 2010
 
Date Event Description
21 September 2016 Amended Contact details updated.
11 February 2015 Amended Contact details updated.
27 March 2014 Amended Contact details updated.
7 April 2013 New citation required but conclusions
have not changed
Text updated. One new study added to excluded studies (Caudill
2011). The update has not altered the conclusions from the last
publication of this review.
26 October 2012 New search has been performed Updated search of MEDLINE, EMBASE, CENTRAL, and PsycINFO.
 
C O N T R I B U T I O N S   O F   A U T H O R S
ZB and SH screened abstracts, supervised by FB and AR. All authors contributed to writing the update.
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D E C L A R A T I O N S   O F   I N T E R E S T
Zachary Beevers: none known
Sana Hussain: none known
Florien W Boele: none known
Alasdair G Rooney: none known
S O U R C E S   O F   S U P P O R T
Internal sources
• NHS Lothian Neuro-oncology Endowment Fund, UK
Salary for AR
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We changed the title to specify that the review was of interventions for the treatment of depression (as opposed to prevention).
We searched the British Nursing Index in place of CINAHL (Cumulative Index to Nursing and Allied Health Literature) because CINAHL was
not available on Ovid. We did not search CancerLit because it is covered by MEDLINE. We did not search Applied Science and Technology
Plus, as it is an engineering database. General Science Plus could not be accessed from Edinburgh University. The search strategy outlined
in the protocol was altered, as necessary, for individual databases; for full details see the Appendices.
We did not widen our search terms to include psychostimulants and acetylcholinesterase inhibitors as we said we would in the original
protocol because publications on these drugs came up in the search, indicating that our search strategy was already adequate.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antidepressive Agents  [adverse effects]  [*therapeutic use];  Brain Neoplasms  [*psychology];  Depression  [*drug therapy]  [etiology]
MeSH check words
Humans
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